MYELOVAX Trademark

Trademark Overview

On Monday, December 19, 2022, a trademark application was filed for MYELOVAX with the United States Patent and Trademark Office. The USPTO has given the MYELOVAX trademark a serial number of 97722425. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Saturday, November 23, 2024. This trademark is owned by Meridian Therapeutics Inc.. The MYELOVAX trademark is filed in the Pharmaceutical Products category with the following description:

Human vaccine preparations; Therapeutic vaccines; Vaccine preparations; Vaccines; Veterinary vaccines

General Information

Serial Number97722425
Word MarkMYELOVAX
Filing DateMonday, December 19, 2022
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateSaturday, November 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 31, 2023

Trademark Statements

Goods and ServicesHuman vaccine preparations; Therapeutic vaccines; Vaccine preparations; Vaccines; Veterinary vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, January 15, 2023
Primary Code005
First Use Anywhere DateFriday, May 20, 2005
First Use In Commerce DateFriday, May 20, 2005

Trademark Owner History

Party NameMeridian Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLehi,, UT 84043
Party NameMeridian Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLehi,, UT 84043

Trademark Events

Event DateEvent Description
Thursday, December 22, 2022NEW APPLICATION ENTERED
Sunday, January 15, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 20, 2023ASSIGNED TO EXAMINER
Monday, September 25, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 11, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 31, 2023PUBLISHED FOR OPPOSITION
Tuesday, October 31, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 26, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, May 24, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, May 24, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, May 24, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, June 26, 2024SOU EXTENSION 1 FILED
Thursday, June 27, 2024TEAS PETITION TO REVIVE RECEIVED
Thursday, June 27, 2024NOTICE OF REVIVAL - E-MAILED
Thursday, June 27, 2024PETITION TO REVIVE-GRANTED
Thursday, June 27, 2024SOU EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, July 2, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, July 2, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, July 2, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 20, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 21, 2024SOU EXTENSION 1 GRANTED
Wednesday, August 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 21, 2024USE AMENDMENT FILED
Thursday, November 21, 2024TEAS STATEMENT OF USE RECEIVED
Saturday, November 23, 2024STATEMENT OF USE PROCESSING COMPLETE

Related Keywords

myelovax vaccines preparations vaccine veterinary therapeutic human